Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

The 24 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $501.42, which forecasts a 11.54% increase in the stock price over the next year. The lowest target is $411 and the highest is $575.

Price Target: $501.42 (+11.54%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$411	$501.42	$525	$575
Change	-8.57%	+11.54%	+16.79%	+27.91%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
Strong Buy	8	8	8	8	7	8
Buy	6	8	8	8	9	11
Hold	10	9	10	10	8	8
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	24	25	26	26	24	27

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
William Pickering Bernstein	Bernstein	Hold → Buy Upgrades n/a	Hold → Buy	Upgrades	n/a	n/a	Jan 12, 2026
Michael Yee UBS	UBS	Strong Buy Initiates $546 → $535	Strong Buy	Initiates	$546 → $535	+19.01%	Jan 7, 2026
Andy Chen Wolfe Research	Wolfe Research	Hold → Buy Upgrades $548	Hold → Buy	Upgrades	$548	+21.91%	Jan 6, 2026
David Risinger Leerink Partners	Leerink Partners	Buy Maintains $456 → $525	Buy	Maintains	$456 → $525	+16.79%	Dec 29, 2025
Mohit Bansal Wells Fargo	Wells Fargo	Buy Maintains $460 → $515	Buy	Maintains	$460 → $515	+14.56%	Dec 10, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.23B

Increased by 11.01%

from 11.02B

Revenue Next Year

13.30B

Increased by 8.74%

from 12.23B

EPS This Year

18.69

from -2.08

EPS Next Year

20.45

Increased by 9.43%

from 18.69

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	6.21B	7.57B	8.93B	9.87B	11.02B	12.23B	13.30B
Revenue Growth	49.08%	22.06%	17.91%	10.51%	11.66%	11.01%	8.74%
EPS	10.29	9.01	12.82	13.89	-2.08	18.69	20.45
EPS Growth	128.16%	-12.44%	42.29%	8.35%	-	-	9.43%
Forward PE	-	-	-	-	-	24.06	21.98
No. Analysts	-	-	-	-	-	35	33

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	12.8B	14.8B
Avg	12.2B	13.3B
Low	11.7B	11.8B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	16.4%	21.3%
Avg	11.0%	8.7%
Low	5.8%	-3.4%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	20.11	24.93
Avg	18.69	20.45
Low	15.29	17.79

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	33.4%
Avg	-	9.4%
Low	-	-4.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.